Evidence map›Paper›PMID 37621921›Full record

ArticleInfluenza and other respiratory viruses2023

Age-specific severity of severe acute respiratory syndrome coronavirus 2 in February 2020 to June 2021 in the Netherlands.

Pieter T de Boer, Jan van de Kassteele, Eric R A Vos, Liselotte van Asten, Dave A Dongelmans, Arianne B van Gageldonk-Lafeber, Gerco den Hartog, Agnetha Hofhuis, Fiona van der Klis, Dylan W de Lange and 6 more

Abstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Contact behaviour before, during and after the COVID-19 pandemic in the Netherlands: evidence from contact surveys, 2016 to 2017 and 2020 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Pieter T de BoerCenter for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands.
Jan van de KassteeleCenter for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands.
Eric R A VosCenter for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands.
Liselotte van AstenCenter for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands.
Dave A DongelmansDepartment of Intensive Care Medicine Amsterdam UMC (location AMC) Amsterdam The Netherlands.
Arianne B van Gageldonk-LafeberCenter for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands.
Gerco den HartogCenter for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands.
Agnetha HofhuisCenter for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands.
Fiona van der KlisCenter for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands.
Dylan W de LangeIntensive Care, University Medical Center Utrecht University of Utrecht Utrecht The Netherlands.
Lenny StoeldraijerStatistics Netherlands The Hague The Netherlands.
RIVM COVID‐19 epidemiology and surveillance team
Hester E de MelkerCenter for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands.
Eveline GeubbelsCenter for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands.
Susan van den HofCenter for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands.
Jacco WallingaCenter for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The severity of Severe Acute Respiratory Syndrome Coronavirus 2 infection varies with age and time. Here, we quantify how age-specific risks of hospitalization, intensive care unit (ICU) admission, and death upon infection changed from February 2020 to June 2021 in the Netherlands. Methods: A series of large representative serology surveys allowed us to estimate age-specific numbers of infections in three epidemic periods (late-February 2020 to mid-June 2020, mid-June 2020 to mid-February 2021, and mid-February 2021 to late-June 2021). We accounted for reinfections and breakthrough infections. Severity measures were obtained by combining infection numbers with age-specific numbers of hospitalization, ICU admission, and excess all-cause deaths. Results: There was an accelerating, almost exponential, increase in severity with age in each period. The rate of increase with age was the highest for death and the lowest for hospitalization. In late-February 2020 to mid-June 2020, the overall risk of hospitalization upon infection was 1.5% (95% confidence interval [CI] 1.3-1.8%), the risk of ICU admission was 0.36% (95% CI: 0.31-0.42%), and the risk of death was 1.2% (95% CI: 1.0-1.4%). The risk of hospitalization was significantly increased in mid-June 2020 to mid-February 2021, while the risk of ICU admission remained stable over time. The risk of death decreased over time, with a significant drop among ≥70-years-olds in mid-February 2021 to late-June 2021; COVID-19 vaccination started early January 2021. Conclusion: Whereas the increase in severity of Severe Acute Respiratory Syndrome Coronavirus 2 with age remained stable, the risk of death upon infection decreased over time. A significant drop in risk of death among elderly coincided with the introduction of COVID-19 vaccination.

Indexed as

COVID-19SARS-CoV-2AgedAge FactorsCOVID-19 VaccinesHumansNetherlandsCOVID-19 VaccinesCOVID‐19disease severityepidemiologyinfection fatality ratioSARS‐CoV‐2

Identifiers

PMID37621921
PMCPMC10444602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.